Drugs / cyclic di-adenosine monophosphate
cyclic di-adenosine monophosphate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05208710 | Nov 2022 → Dec 2027 expected | human papilloma virus infection | German Cancer Research Center | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cyclic di-adenosine monophosphate | “the di-nucleotide adjuvant cyclic di-adenosine monophosphate (used abbreviations: cyclic di-AMP / c-di-AMP/ cdA), an inducer of cellular STING” NCT05208710 ↗ |
| Known as | c-di-AMP | “the di-nucleotide adjuvant cyclic di-adenosine monophosphate (used abbreviations: cyclic di-AMP / c-di-AMP/ cdA), an inducer of cellular STING” NCT05208710 ↗ |
| Known as | cdA | “the di-nucleotide adjuvant cyclic di-adenosine monophosphate (used abbreviations: cyclic di-AMP / c-di-AMP/ cdA), an inducer of cellular STING” NCT05208710 ↗ |
| Known as | cyclic di-AMP | “the di-nucleotide adjuvant cyclic di-adenosine monophosphate (used abbreviations: cyclic di-AMP / c-di-AMP/ cdA), an inducer of cellular STING” NCT05208710 ↗ |
| Action | Activate | “an inducer of cellular STING” NCT05208710 ↗ |
| Modality | Oligonucleotide (other) | “the di-nucleotide adjuvant cyclic di-adenosine monophosphate” NCT05208710 ↗ |